Integrated and standardized NGS workflows for Personalised therapy

Akronyymi

Instand-NGS4P

Rahoitetun hankkeen kuvaus

Instand-NGS4P is a 65-month PCP project federating 7 leading medical centers (two are coordinating ERNs) as buyers’ group with major experience in using different NGS platforms in research and routine diagnostics. The consortium is further strengthened by European patient advocacy groups, a standardization organization and partners participating in the European infrastructures BBMRI-ERIC, ELIXIR as well as several NGS-related EU programs to cover all technical aspects and transversal needs & requirements. Driven by patient and clinical needs, innovative NGS workflows from sample-pre-analytics to medical decision making will be developed. The modular design of the workflow will particularly enable SEMs to contribute, and provides flexibility to adopt emerging user needs and technologies. Specifications will address regulatory requirements for IVDs and refer to international standards and requests development of reference materials and implementation of EQA schemes covering the whole workflow. R&D suppliers will be selected based on a public tender all along this PCP process in 3 phases according to the best-value for money solution. The 3 phases foresee the leverage of 4 technical modules (pre-analytics, sequencing, bioinformatics, e-reporting/e-medication) and their standardized interfaces – from design (Phase 1) to prototypes (Phase 2), and full integration in Phase 3. At the end, this PCP will provide 2 fully integrated, standardized NGS workflows for routine diagnostics of common and rare cancers from adults to children. In order to enable broad implementation in healthcare systems throughout Europe and beyond and to increase benefit to patients a series of support activities are planned including communication and dissemination activities targeting a broad stakeholder community, development of training and education material for healthcare professionals and patients, health economic assessment and engagement with healthcare payers and policy makers.
Näytä enemmän

Aloitusvuosi

2020

Päättymisvuosi

2025

Myönnetty rahoitus

120 960 €
Participant
ST. ANNA KINDERKREBSFORSCHUNG GMBH (AT)
316 953 €
Participant
BIOXPEDIA AS (DK)
39 015 €
Participant
FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA (IT)
93 690 €
Participant
FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA (IT)
13 500 €
Third party
INSTITUTUL ONCOLOGIC PROF DR ION CHIRICUTA CLUJ-NAPOCA (RO)
6 390 €
Third party
INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE (PT)
13 500 €
Third party
ORGANISATION OF EUROPEAN CANCER INSTITUTES (BE)
41 593.5 €
Participant
CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD (FR)
261 257.18 €
Participant
DIN DEUTSCHES INSTITUT FUER NORMUNG E.V. (DE)
70 200 €
Participant
DIN DEUTSCHES INSTITUT FUER NORMUNG EV (DE)
70 200 €
Participant
MEDIZINISCHE UNIVERSITAT GRAZ (AT)
8 140 561.32 €
Coordinator
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL (DE)
Third party
UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN (DE)
266 657.18 €
Participant
UNIVERSITA DEGLI STUDI DI FIRENZE (IT)
263 957.18 €
Participant
THE UNIVERSITY OF MANCHESTER (UK)
100 980 €
Participant
UNIVERZA V LJUBLJANI (SI)
121 635 €
Participant
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT)
333 727.83 €
Participant
TECHNISCHE UNIVERSITAET MUENCHEN (DE)
124 503.75 €
Participant
THE UNIVERSITY OF LIVERPOOL (UK)
152 685 €
Participant
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (NL)
315 514.8 €
Participant

Myönnetty summa

10 998 128 €

Rahoittaja

Euroopan unioni

Rahoitusmuoto

Pre-Commercial Procurement

Puiteohjelma

Horizon 2020 Framework Programme

Haku

Ohjelman osa
Health (5290)
Methods and data (5305)
Aihe
Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis (SC1-BHC-10-2019)
Haun tunniste
H2020-SC1-2019-Single-Stage-RTD

Muut tiedot

Rahoituspäätöksen numero

874719

Tunnistetut aiheet

health care